Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). - PubMed - NCBI

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). - PubMed - NCBI

Therapie. 2017 Jan 30. pii: S0040-5957(17)30006-9. doi: 10.1016/j.therap.2016.09.014. [Epub ahead of print]

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

Picard N1, Boyer JC2, Etienne-Grimaldi MC3, Barin-Le Guellec C4, Thomas F5, Loriot MA6; French National Network of Pharmacogenetics (RNPGx).

Author information

Abstract

More than 50 laboratories offer pharmacogenetic testing in France. These tests are restricted to a limited number of indications: prevention of serious adverse drug reactions; choice of most appropriate therapeutic option; dose adjustment for a specific drug. A very small proportion of these tests are mentioned in drug information labeling and the data provided (if any) are generally insufficient to ascertain whether a test is required and if it is useful. This article discusses the rationale for evaluating the performance and clinical usefulness of pharmacogenetics and provides, on behalf of the French national network of pharmacogenetics (RNPGx), three levels of recommendation for testing: essential, advisable, and possibly helpful.

Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

KEYWORDS:

Clinical biology; Level of evidence; Recommendations

PMID:

 

28237406

 

DOI:

 

10.1016/j.therap.2016.09.014

[PubMed - as supplied by publisher]